These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 37755820)

  • 1. Economic Evaluation of Angiotensin-Neprilysin Inhibitors Across Ejection Fractions.
    Cohen LP; Bellows BK
    JAMA Cardiol; 2023 Nov; 8(11):1048-1049. PubMed ID: 37755820
    [No Abstract]   [Full Text] [Related]  

  • 2. Angiotensin-Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: You Win Some, You Lose Some.
    Ventura HO; Lavie CJ; Mehra MR
    J Am Coll Cardiol; 2023 Jul; 82(1):13-15. PubMed ID: 37220861
    [No Abstract]   [Full Text] [Related]  

  • 3. Renal Effects and Associated Outcomes During Angiotensin-Neprilysin Inhibition in Heart Failure.
    Damman K; Gori M; Claggett B; Jhund PS; Senni M; Lefkowitz MP; Prescott MF; Shi VC; Rouleau JL; Swedberg K; Zile MR; Packer M; Desai AS; Solomon SD; McMurray JJV
    JACC Heart Fail; 2018 Jun; 6(6):489-498. PubMed ID: 29655829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Health and Economic Evaluation of Sacubitril-Valsartan for Heart Failure Management.
    Bhatt AS; Vaduganathan M; Claggett BL; Fonarow GC; Packer M; Pfeffer MA; Shah SJ; Shen X; Cristino J; McMurray JJV; Solomon SD; Gaziano TA
    JAMA Cardiol; 2023 Nov; 8(11):1041-1048. PubMed ID: 37755814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-Effectiveness of Switching Patients With Heart Failure and Reduced Ejection Fraction to Sacubitril/Valsartan: The Australian Perspective.
    Chin KL; Zomer E; Wang BH; Liew D
    Heart Lung Circ; 2020 Sep; 29(9):1310-1317. PubMed ID: 32303468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiotensin-Neprilysin Inhibition as a Paradigm for All?
    Vaduganathan M; Desai AS
    Curr Cardiol Rep; 2016 Nov; 18(11):115. PubMed ID: 27747488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin-neprilysin inhibition and renal outcomes across the spectrum of ejection fraction in heart failure.
    Mc Causland FR; Lefkowitz MP; Claggett B; Packer M; Senni M; Gori M; Jhund PS; McGrath MM; Rouleau JL; Shi V; Swedberg K; Vaduganathan M; Zannad F; Pfeffer MA; Zile M; McMurray JJV; Solomon SD
    Eur J Heart Fail; 2022 Sep; 24(9):1591-1598. PubMed ID: 34989105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Effects of Angiotensin Receptor-Neprilysin Inhibition on Major Coronary Events in Patients With Acute Myocardial Infarction: Insights From the PARADISE-MI Trial.
    Mehran R; Steg PG; Pfeffer MA; Jering K; Claggett B; Lewis EF; Granger C; Køber L; Maggioni A; Mann DL; McMurray JJV; Rouleau JL; Solomon SD; Ducrocq G; Berwanger O; De Pasquale CG; Landmesser U; Petrie M; Leng DSK; van der Meer P; Lefkowitz M; Zhou Y; Braunwald E
    Circulation; 2022 Dec; 146(23):1749-1757. PubMed ID: 36321459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiotensin-Neprilysin Inhibition and Renal Outcomes in Heart Failure With Preserved Ejection Fraction.
    Mc Causland FR; Lefkowitz MP; Claggett B; Anavekar NS; Senni M; Gori M; Jhund PS; McGrath MM; Packer M; Shi V; Van Veldhuisen DJ; Zannad F; Comin-Colet J; Pfeffer MA; McMurray JJV; Solomon SD
    Circulation; 2020 Sep; 142(13):1236-1245. PubMed ID: 32845715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Consider Everything When Prescribing Sacubitril/Valsartan: Perfection Is the Enemy of Good.
    Gottlieb SS; Ahmed T
    J Am Coll Cardiol; 2020 Sep; 76(9):1049-1050. PubMed ID: 32854839
    [No Abstract]   [Full Text] [Related]  

  • 11. Effects of angiotensin receptor neprilysin inhibition on P-wave dispersion in heart failure with reduced ejection fraction.
    Okutucu S; Fatihoglu SG; Sabanoglu C; Bursa N; Sayin BY; Aksoy H; Oto A
    Herz; 2021 Apr; 46(Suppl 1):69-74. PubMed ID: 31796977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-World Experience of Angiotensin Receptor-Neprilysin Inhibition in Reduced Ejection Fraction Heart Failure Patients With Advanced Kidney Disease.
    Chang HY; Lin CC; Chao CJ; Lin YC; Wang YC; Liao CT; Huang JL; Lee YH; Huang CY; Chien LN; Hsu CY
    Mayo Clin Proc; 2023 Jan; 98(1):88-99. PubMed ID: 36109207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction.
    Solomon SD; McMurray JJV; Anand IS; Ge J; Lam CSP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Redfield MM; Rouleau JL; van Veldhuisen DJ; Zannad F; Zile MR; Desai AS; Claggett B; Jhund PS; Boytsov SA; Comin-Colet J; Cleland J; Düngen HD; Goncalvesova E; Katova T; Kerr Saraiva JF; Lelonek M; Merkely B; Senni M; Shah SJ; Zhou J; Rizkala AR; Gong J; Shi VC; Lefkowitz MP;
    N Engl J Med; 2019 Oct; 381(17):1609-1620. PubMed ID: 31475794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition.
    Hubers SA; Brown NJ
    Circulation; 2016 Mar; 133(11):1115-24. PubMed ID: 26976916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progress and prospects of Sacubitril/Valsartan: Based on heart failure with preserved ejection fraction.
    Jia R; Ji Y; Sun D
    Biomed Pharmacother; 2022 Nov; 155():113701. PubMed ID: 36116249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiotensin Receptor-Neprilysin Inhibition in Heart Failure With Reduced Ejection Fraction: A Paradigm for All?
    Konstam MA
    JACC Heart Fail; 2016 Oct; 4(10):823-825. PubMed ID: 27614938
    [No Abstract]   [Full Text] [Related]  

  • 17. Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: an analysis of the PARAMOUNT trial.
    Jhund PS; Claggett B; Packer M; Zile MR; Voors AA; Pieske B; Lefkowitz M; Shi V; Bransford T; McMurray JJ; Solomon SD
    Eur J Heart Fail; 2014 Jun; 16(6):671-7. PubMed ID: 24692284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of angiotensin-neprilysin inhibition compared to angiotensin inhibition on ventricular arrhythmias in reduced ejection fraction patients under continuous remote monitoring of implantable defibrillator devices.
    de Diego C; González-Torres L; Núñez JM; Centurión Inda R; Martin-Langerwerf DA; Sangio AD; Chochowski P; Casasnovas P; Blazquéz JC; Almendral J
    Heart Rhythm; 2018 Mar; 15(3):395-402. PubMed ID: 29146274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improvement in quality of life with sacubitril/ /valsartan in cardiac resynchronization non-responders: The RESINA (RESynchronization plus an Inhibitor of Neprilysin/Angiotensin) registry.
    Rubio Campal JM; Del Castillo H; Arroyo Rivera B; de Juan Bitriá C; Taibo Urquia M; Sánchez Borque P; Miracle Blanco Á; Bravo Calero L; Martí Sánchez D; Tuñón Fernández J
    Cardiol J; 2021; 28(3):402-410. PubMed ID: 33634846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neprilysin inhibition with sacubitril/valsartan in the treatment of heart failure: mortality bang for your buck.
    Ansara AJ; Kolanczyk DM; Koehler JM
    J Clin Pharm Ther; 2016 Apr; 41(2):119-27. PubMed ID: 26992459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.